Literature DB >> 6888549

Cell lines producing human T-cell lymphoma virus show altered HLA expression.

D L Mann, M Popovic, P Sarin, C Murray, M S Reitz, D M Strong, B F Haynes, R C Gallo, W A Blattner.   

Abstract

Human T-cell leukaemia/lymphoma virus (HTLV) can be identified in fresh and cultured T-lymphocytes from patients with adult T-cell malignancies. HLA typing of the peripheral blood lymphocytes and cultured cell lines from the patient from which the virus was originally isolated suggested the expression of additional HLA-A and -B locus antigens on the HTLV positive cultured T-cells that were not present on the EBV transformed B-cell line or on the peripheral blood lymphocytes. Peripheral blood lymphocytes (PBLs) and T-cell lines established from patients and cord blood lymphocytes, infected with virus by co-culture with T-cell lines, were typed for HLA antigens with alloantisera and in addition tested for reactivity with a monoclonal antibody (4D12) which recognizes a polymorphic HLA class-I antigen. In all HTLV positive cells, with demonstrable provirus replication, altered HLA alloantigen expression was observed. This may be explained by the observations reported in the accompanying paper which shows homology between the envelope gene region of HTLV and the region of an HLA-B locus gene which codes for the extracellular portion of a class I histocompatibility antigen.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6888549     DOI: 10.1038/305058a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  22 in total

1.  Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein.

Authors:  J M Johnson; C Nicot; J Fullen; V Ciminale; L Casareto; J C Mulloy; S Jacobson; G Franchini
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Impairment of MHC class I transcription in a mutant bovine B cell line.

Authors:  J S Harms; G A Splitter
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

3.  Application of DNA fingerprints for cell-line individualization.

Authors:  D A Gilbert; Y A Reid; M H Gail; D Pee; C White; R J Hay; S J O'Brien
Journal:  Am J Hum Genet       Date:  1990-09       Impact factor: 11.025

4.  Polymorphic and autoreactive H-2-specific monoclonal antibody isolated after injections of syngeneic Sendai virus-coated lymphocytes.

Authors:  A Opolski; F Kievits; P Iványi
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

Review 5.  Hijacking the T-cell communication network by the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) p12 and p8 proteins.

Authors:  Nancy Van Prooyen; Vibeke Andresen; Heather Gold; Izabela Bialuk; Cynthia Pise-Masison; Genoveffa Franchini
Journal:  Mol Aspects Med       Date:  2010-07-29

Review 6.  Use of cultured human tissues and cells in carcinogenesis research.

Authors:  E W Gabrielson; C C Harris
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

7.  Absence of antibodies to HTLV-I/II in French patients with hematological malignancies.

Authors:  G Agius; V Vaillant; R J Biggar; A Brizard; S Ranger; G Dindinaud; M Castets
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

Review 8.  Human T-lymphotropic retroviruses in adult T-cell leukemia-lymphoma and acquired immune deficiency syndrome.

Authors:  P S Sarin; R C Gallo
Journal:  J Clin Immunol       Date:  1984-11       Impact factor: 8.317

9.  IgG heavy chain allotype (Gm), a genetic marker for human chromosome 14q32, and haematopoietic malignancies.

Authors:  Y Nakao; H Matsumoto; K Tsuji; T Miyazaki; T Masaoka; S Nakayama; K Kinoshita; T Shingami; T Matsui; T Fujita
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

10.  Deficient expression of class-I HLA in some cases of acute leukemia.

Authors:  W L Elkins; A Pickard; G R Pierson
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.